Rama K Mallampalli Selected Research

Inflammation (Inflammations)

1/2023	ISGylation of NF-κBp65 by SCFFBXL19 E3 Ligase Diminishes Endothelial Inflammation.
1/2020	Increased Alternative Complement Pathway Function and Improved Survival during Critical Illness.
1/2020	Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.
12/2019	Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for Acute Respiratory Distress Syndrome.
1/2019	The SCFFBXO3 ubiquitin E3 ligase regulates inflammation in atherosclerosis.
11/2017	The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia.
1/2017	SCFFBXO17 E3 ligase modulates inflammation by regulating proteasomal degradation of glycogen synthase kinase-3β in lung epithelia.
1/2017	Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation.
1/2017	IL-4 Induces IL17Rb Gene Transcription in Monocytic Cells with Coordinate Autocrine IL-25 Signaling.
1/2016	Crystal structure and interaction studies of the human FBxo3 ApaG domain.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rama K Mallampalli Research Topics

Disease

19	Infections 01/2023 - 03/2006
14	Inflammation (Inflammations) 01/2023 - 10/2010
12	Lung Injury 02/2024 - 04/2002
11	Acute Lung Injury 05/2023 - 01/2003
10	Pneumonia (Pneumonitis) 01/2022 - 10/2010
8	Neoplasms (Cancer) 01/2021 - 02/2013
7	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 05/2023 - 02/2015
5	Sepsis (Septicemia) 05/2023 - 10/2006
5	Lung Diseases (Lung Disease) 05/2015 - 08/2004
4	Critical Illness (Critically Ill) 05/2023 - 05/2013
4	COVID-19 01/2023 - 08/2020
4	Virus Diseases (Viral Diseases) 12/2022 - 06/2004
3	Bacterial Pneumonia 05/2024 - 10/2010
3	Hypoxia (Hypoxemia) 11/2023 - 12/2011
3	Human Influenza (Influenza) 01/2023 - 01/2021
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 03/2014
3	Bacterial Infections (Bacterial Infection) 05/2013 - 04/2007
3	Pseudomonas Infections 05/2011 - 04/2007
2	Breakthrough Infections 04/2024 - 03/2024
2	Wounds and Injuries (Trauma) 06/2023 - 09/2015
2	Respiratory Insufficiency (Respiratory Failure) 05/2023 - 02/2015
2	Fibrosis (Cirrhosis) 01/2020 - 01/2018
2	Edema (Dropsy) 12/2019 - 02/2015
2	Atherosclerosis 01/2019 - 12/2013
2	Idiopathic Pulmonary Fibrosis 01/2018 - 12/2015
2	Multiple Myeloma 01/2018 - 01/2014
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 05/2015 - 08/2010
2	Tangier Disease 12/2007 - 05/2007
1	Disease Progression 05/2023
1	Complement Factor H Deficiency 05/2023
1	Pulmonary Hypertension 02/2023
1	Vascular Remodeling 01/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Emphysema 01/2020

Drug/Important Bio-Agent (IBA)

22	Proteins (Proteins, Gene)FDA Link 05/2024 - 12/2007
11	Surface-Active Agents (Surfactants)IBA 05/2015 - 04/2002
9	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2023 - 01/2011
9	UbiquitinIBA 12/2022 - 06/2012
7	CytokinesIBA 01/2023 - 04/2002
5	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2022 - 09/2013
5	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 04/2007
5	LipidsIBA 05/2011 - 01/2003
4	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2018
4	F-Box ProteinsIBA 02/2016 - 06/2012
4	Phosphatidylcholines (Phosphatidylcholine)IBA 05/2011 - 04/2002
3	Messenger RNA (mRNA)IBA 04/2024 - 01/2017
3	LigandsIBA 12/2022 - 12/2011
3	AntibodiesIBA 11/2020 - 05/2015
3	SmokeIBA 01/2020 - 03/2014
3	Cardiolipins (Cardiolipin)IBA 11/2017 - 10/2010
2	Semaxinib (SU5416)IBA 11/2023 - 02/2023
2	Biomarkers (Surrogate Marker)IBA 05/2023 - 12/2019
2	Fatty Acids (Saturated Fatty Acids)IBA 05/2023 - 04/2014
2	Complement System Proteins (Complement)IBA 05/2023 - 01/2020
2	Toll-Like Receptor 3IBA 02/2023 - 01/2023
2	Ligases (Synthetase)IBA 01/2023 - 06/2012
2	InterferonsIBA 12/2022 - 01/2021
2	Cullin Proteins (Cullins)IBA 12/2022 - 01/2019
2	Antiviral Agents (Antivirals)IBA 12/2022 - 01/2021
2	Heme (Haem)IBA 01/2021 - 12/2011
2	Neutralizing AntibodiesIBA 11/2020 - 08/2020
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020 - 01/2018
2	Phosphotransferases (Kinase)IBA 01/2020 - 04/2014
2	Deubiquitinating EnzymesIBA 07/2019 - 01/2018
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 03/2014
2	EnzymesIBA 01/2018 - 05/2011
2	LipopolysaccharidesIBA 12/2016 - 10/2015
2	Pulmonary Surfactants (Pulmonary Surfactant)IBA 05/2015 - 04/2014
2	Calmodulin (Calcium-Dependent Activator Protein)IBA 02/2013 - 05/2011
2	SphingolipidsIBA 06/2004 - 01/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2003 - 04/2002
1	EndotoxinsIBA 02/2024
1	acylcarnitineIBA 05/2023
1	octanoylcarnitineIBA 05/2023
1	3-methylhistidineIBA 05/2023
1	lisofyllineIBA 05/2023
1	Complement Factor B (Factor B)IBA 05/2023
1	Complement Factor H (Factor H)IBA 05/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2023
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 02/2023
1	Poly I-CIBA 01/2023
1	Hemagglutinins (Hemagglutinin)IBA 01/2023
1	Angiotensin-Converting Enzyme 2IBA 01/2023
1	Leucine-Rich Repeat ProteinsIBA 01/2023
1	NF-kappa B (NF-kB)IBA 01/2023
1	Axonemal DyneinsIBA 01/2023
1	LysophospholipidsIBA 01/2022
1	phosphatidylethanolamineIBA 01/2022
1	Interferon Receptors (Interferon Receptor)IBA 01/2021
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 01/2021
1	ChromatinIBA 01/2021
1	Heme Oxygenase-1IBA 01/2021
1	coactivator-associated arginine methyltransferase 1IBA 01/2021
1	maltoporinsIBA 01/2021
1	Interferon LambdaIBA 01/2021
1	Fibronectins (Fibronectin)IBA 01/2020
1	CollagenIBA 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2020

Therapy/Procedure

6	Therapeutics 06/2023 - 01/2014
2	Critical Care (Surgical Intensive Care) 01/2022 - 01/2019